Share on StockTwits

DexCom (NASDAQ:DXCM) VP Richard Doubleday sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $35.59, for a total value of $142,360.00. Following the sale, the vice president now directly owns 126,136 shares in the company, valued at approximately $4,489,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of DexCom (NASDAQ:DXCM) traded up 1.63% on Friday, hitting $36.72. 663,140 shares of the company’s stock traded hands. DexCom has a one year low of $19.93 and a one year high of $49.83. The stock’s 50-day moving average is $33.04 and its 200-day moving average is $37.32. The company’s market cap is $2.751 billion.

DexCom (NASDAQ:DXCM) last released its earnings data on Thursday, May 1st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

DXCM has been the subject of a number of recent research reports. Analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of DexCom from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $38.36.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.